Metastasis is the process by which malignant cancer cells leave a primary tumour, travel to another part of the body, establish themselves in a distant or otherwise separate site and form a secondary tumour. It is a multistep biological process rather than a single event. Cancer cells must acquire or exploit properties that allow them to detach from the primary tumour, invade surrounding tissue, enter blood or lymphatic vessels, survive transport, leave the circulation and successfully colonise a new microenvironment.
Metastatic disease is clinically important because secondary tumours can impair the function of vital organs and substantially complicate treatment. The process is influenced by tumour genetics, cellular plasticity, interactions with stromal cells, immune responses, blood flow, tissue structure and the biological characteristics of the destination organ.
Metastatic spread commonly involves local invasion followed by intravasation into blood or lymphatic vessels. Cancer cells may alter adhesion molecules and interact with extracellular matrix components to move through surrounding tissue. Once inside circulation, many malignant cells die because of physical stress or immune attack, meaning that only a small fraction may ultimately establish successful metastases. Cells that survive can circulate individually or in clusters and may interact with platelets and other blood components.
At distant sites, extravasation allows tumour cells to leave vessels and enter tissue. Successful colonisation then requires adaptation to the local environment, access to nutrients, avoidance of immune destruction and often the establishment of new blood supply. Each stage presents biological barriers that explain why metastatic spread is inefficient despite its major clinical consequences.
Metastasis is not random in every cancer. Certain cancers show characteristic patterns of dissemination that reflect anatomical routes, circulation, adhesion mechanisms, tissue compatibility and molecular interactions. Lymphatic spread commonly involves regional lymph nodes, while haematogenous spread can reach organs supplied by systemic circulation. The concept of organ specific metastatic tropism describes the tendency of particular tumour types to establish metastases in particular tissues.
This can involve molecular interactions between tumour cells and host tissues as well as characteristics of the target microenvironment. The pre metastatic niche is a proposed condition in which factors released by a primary tumour modify distant tissues before arrival of tumour cells, potentially making those tissues more supportive of later colonisation. This field illustrates that metastatic disease involves interactions between tumour and host rather than tumour cells acting independently.
The tumour microenvironment is central to metastatic progression. Cancer cells interact with fibroblasts, endothelial cells, immune cells, extracellular matrix and signalling molecules. These interactions can promote invasion, angiogenesis, survival and adaptation. Epithelial mesenchymal transition is a biological programme often discussed in relation to tumour cell plasticity, although cancer cells can display partial or context dependent states rather than following a simple binary transition.
Angiogenesis allows growing tumours to obtain oxygen and nutrients and provides routes through which tumour cells may enter circulation. Immune cells can sometimes destroy tumour cells but can also create inflammatory conditions that support tumour progression. The metastatic process is therefore influenced by a dynamic ecosystem surrounding malignant cells.
Metastatic tumours retain genetic and pathological relationships with their primary cancers, although they can acquire additional alterations during progression. A biopsy of a metastatic lesion can therefore help establish the origin of an unknown malignancy and may reveal clinically important differences from the original tumour. Pathologists use morphology, immunohistochemistry and molecular testing to distinguish metastatic disease from an unrelated primary tumour.
Clinical staging systems commonly distinguish localised disease from regional and distant spread, with distant metastasis often substantially affecting stage and treatment planning. The presence, number, anatomical distribution and resectability of metastatic lesions can influence management. Some patients have limited metastatic disease that can be treated with surgery, radiotherapy or local ablative approaches, while widespread disease often requires systemic treatment.
Treatment of Metastasis depends on tumour type, extent of disease, molecular characteristics, previous therapy, symptoms and patient circumstances. Systemic therapies can include chemotherapy, endocrine therapy, targeted therapy and immunotherapy, while surgery or radiotherapy may be used for selected metastatic deposits. Treatment can be intended to control disease, relieve symptoms, prevent complications or occasionally achieve long term disease control in selected circumstances. Metastatic cancer should not automatically be regarded as biologically identical across all tumour types because survival and therapeutic options vary substantially. Some metastatic cancers can remain controlled for prolonged periods, while others progress rapidly. Clinical decisions therefore require information about both the primary cancer and the specific metastatic pattern.
Detecting metastatic disease involves imaging, pathological examination and sometimes molecular testing. Computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound and other techniques can identify suspicious lesions depending on anatomical location and tumour type. Imaging findings may require tissue confirmation because infection, inflammation and benign lesions can sometimes resemble metastases. Blood tests can provide indirect information but usually cannot establish metastatic disease on their own. Circulating tumour DNA and other liquid biopsy approaches are being studied and increasingly used in selected clinical contexts, but their sensitivity varies. Accurate assessment requires correlation among symptoms, examination, imaging, pathology and laboratory findings.
A common misconception is that metastasis is simply cancer cells physically travelling from one organ to another. Successful metastasis requires survival, adaptation and interaction with a new tissue environment, making it an evolutionarily demanding process. Another misconception is that all metastatic deposits behave identically to the primary tumour. Although they share lineage, additional evolution can produce biologically distinct subclones. Research into metastasis focuses on tumour cell plasticity, circulating tumour cells, extracellular vesicles, immune regulation, organ specific microenvironments and mechanisms of therapy resistance. Understanding these processes is important because preventing or controlling metastatic spread remains a central objective of cancer medicine.
